← Leaderboards
Marja T Nevalainen
Thomas Jefferson University
$4,195,518
Attributed
$5,344,437
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $597.2K · FY2006–25$1M$750K$500K$250K$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$5,344,437 · 3
By mechanism
R01$4,979,667 · 2
R21$364,770 · 1
Top collaborators
- Scott M. Dehm4 shared
Most similar at Thomas Jefferson University
Same institution · by research overlap
- Roseann C Schaaf$1,742,581
- Dennis B Leeper$1,908,536
- Kibo Nam$3,822,520
- Theodore J Price$21,784,254
- Inna Chervoneva$3,920,213
Others in their field
Top investigators on “Cancer Patient”
- David Heimbrook · Leidos Biomedical Research, Inc.$436,176,488
- Larry Arthur$370,429,903
- Norman Wolmark · Nsabp Foundation, Inc.$324,028,859
- Gregory H Reaman · National Childhood Cancer Foundation$270,366,096
- Leonard Freedman · Leidos Biomedical Research, Inc.$268,085,841
- Richard A Gibbs · Baylor College Of Medicine$240,560,484
Research focus
Cancer PatientMalignant Neoplasm Of ProstateTumorIn VivoAndrogen ReceptorAndrogensProteinsIn VitroGrowthGenesCellsSignal PathwayBasePathway InteractionsGenetic TranscriptionBehaviorProstateRecurrenceCessation Of LifeMediatingDistantResistanceCell SurvivalSignal Transduction
Grant awards (17)
Pharmacological Jak2 inhibition to overcome androgen receptor aberrations in prostate cancer$597,173
R01 · FY2025 · CA · contact PI
Pharmacological Jak2 inhibition to overcome androgen receptor aberrations in prostate cancer$564,525
R01 · FY2024 · CA · contact PI
Pharmacological Jak2 inhibition to overcome androgen receptor aberrations in prostate cancer$559,451
R01 · FY2023 · CA · contact PI
Pharmacological Jak2 inhibition to overcome androgen receptor aberrations in prostate cancer$576,689
R01 · FY2022 · CA · contact PI
Stat5 in Progression of Prostate Cancer$279,518
R01 · FY2015 · CA · contact PI
Stat5 in Progression of Prostate Cancer$267,260
R01 · FY2015 · CA · contact PI
Stat5 in Progression of Prostate Cancer$259,242
R01 · FY2014 · CA · contact PI
Novel Strategy to Sensitize Prostate Cancer Cells to Radiation$147,089
R21 · FY2014 · CA · contact PI
Novel Strategy to Sensitize Prostate Cancer Cells to Radiation$49,118
R21 · FY2014 · CA · contact PI
Stat5 in Progression of Prostate Cancer$251,198
R01 · FY2013 · CA · contact PI
Novel Strategy to Sensitize Prostate Cancer Cells to Radiation$168,563
R21 · FY2013 · CA · contact PI
Stat5 in Progression of Prostate Cancer$280,898
R01 · FY2012 · CA · contact PI
Stat5 in Progression of Prostate Cancer$267,147
R01 · FY2010 · CA · contact PI
Stat5 in Progression of Prostate Cancer$267,147
R01 · FY2009 · CA · contact PI
Stat5 in Progression of Prostate Cancer$267,147
R01 · FY2008 · CA · contact PI
Stat5 in Progression of Prostate Cancer$267,147
R01 · FY2007 · CA · contact PI
Stat5 in Progression of Prostate Cancer$275,125
R01 · FY2006 · CA · contact PI